These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 9213861)

  • 81. Local cold exposure test with a new arterial photoplethysmographic sensor in healthy controls and patients with secondary Raynaud's phenomenon.
    Hahn M; Hahn C; Jünger M; Steins A; Zuder D; Klyscz T; Büchtemann A; Rassner G; Blazek V
    Microvasc Res; 1999 Mar; 57(2):187-98. PubMed ID: 10049666
    [TBL] [Abstract][Full Text] [Related]  

  • 82. [Sarpogrelate hydrochloride for Raynaud's phenomenon of patients with collagen diseases].
    Kumagai S; Morinobu A; Ozaki S; Nakao K; Ishida H
    Ryumachi; 1998 Jun; 38(3):504-10. PubMed ID: 9721558
    [TBL] [Abstract][Full Text] [Related]  

  • 83. Plasma adrenomedullin and endothelin-1 levels are reduced and Raynaud's phenomenon improved by daily tadalafil administration in male patients with systemic sclerosis.
    Rosato E; Letizia C; Proietti M; Aversa A; Menghi G; Rossi C; Torella E; Cotesta D; Petramala L; Bruzziches R; Spera G; Pisarri S; Salsano F
    J Biol Regul Homeost Agents; 2009; 23(1):23-9. PubMed ID: 19321043
    [TBL] [Abstract][Full Text] [Related]  

  • 84. Acute effects of sublingual nifedipine in patients with Raynaud's phenomenon.
    Gush RJ; Taylor LJ; Jayson MI
    J Cardiovasc Pharmacol; 1987 May; 9(5):628-31. PubMed ID: 2439846
    [TBL] [Abstract][Full Text] [Related]  

  • 85. Objective benefit of nifedipine in the treatment of Raynaud's phenomenon. Double-blind controlled study.
    White CJ; Phillips WA; Abrahams LA; Watson TD; Singleton PT
    Am J Med; 1986 Apr; 80(4):623-5. PubMed ID: 3515931
    [TBL] [Abstract][Full Text] [Related]  

  • 86. Nifedipine treatment of Raynaud's phenomenon in a paediatric age.
    Matucci Cerinic M; Falcini F; Bartolozzi G; Volpi M
    Int J Clin Pharmacol Res; 1985; 5(1):67-9. PubMed ID: 3997315
    [TBL] [Abstract][Full Text] [Related]  

  • 87. [The use of capillary videomicroscopy in the therapeutic assessment of acral vasospastic phenomena: microcirculatory effect of ketanserin and nifedipine].
    Gasser P
    Schweiz Rundsch Med Prax; 1994 Apr; 83(17):511-4. PubMed ID: 8191194
    [TBL] [Abstract][Full Text] [Related]  

  • 88. Calcium entry blocking agents in digital vasospasm (Raynaud's phenomenon).
    Kahan A; Weber S; Amor B; Menkes CJ; Saporta L; Hodara M; Guerin F; Degeorges M
    Eur Heart J; 1983 May; 4 Suppl C():123-9. PubMed ID: 6352267
    [TBL] [Abstract][Full Text] [Related]  

  • 89. Raynaud's phenomenon and nifedipine.
    Kraus A
    J Rheumatol; 1989 Jul; 16(7):1013. PubMed ID: 2597264
    [No Abstract]   [Full Text] [Related]  

  • 90. Effects of calcitonin on limb blood vessels in human obstructive arterial disease.
    Franchi F; Chiarini P; Matassi L; Strazzulla G; Scardi A; Righi D; Nuzzaci G
    Int J Clin Pharmacol Res; 1983; 3(2):115-28. PubMed ID: 6679513
    [TBL] [Abstract][Full Text] [Related]  

  • 91. Low level laser therapy for treatment of primary and secondary Raynaud's phenomenon.
    al-Awami M; Schillinger M; Maca T; Pollanz S; Minar E
    Vasa; 2004 Feb; 33(1):25-9. PubMed ID: 15061044
    [TBL] [Abstract][Full Text] [Related]  

  • 92. Effect of nifedipine in Raynaud's disease: a case report.
    Maguire FW
    Del Med J; 1984 Jul; 56(7):393-8. PubMed ID: 6479385
    [No Abstract]   [Full Text] [Related]  

  • 93. Nifedipine and distal gangrene in Raynaud's phenomenon.
    Rivera Redondo J; Noguerado Asensio A; Alvaro-Gracia Alvaro JM; Laffón Roca A
    J Rheumatol; 1986 Apr; 13(2):464-5. PubMed ID: 3723511
    [No Abstract]   [Full Text] [Related]  

  • 94. The use of longterm nifedipine in a patient with Raynaud's syndrome secondary to mixed connective tissue disease.
    Sarkozi J; McCarthy DD; Lee P
    J Rheumatol; 1984 Jun; 11(3):408-10. PubMed ID: 6737386
    [No Abstract]   [Full Text] [Related]  

  • 95. The anti-platelet effect of nifedipine in patients with systemic sclerosis.
    Rademaker M; Meyrick Thomas RH; Kirby JD; Kovacs IB
    Clin Exp Rheumatol; 1992; 10(1):57-62. PubMed ID: 1551280
    [TBL] [Abstract][Full Text] [Related]  

  • 96. Nifedipine for Raynaud's phenomenon.
    Lancet; 1983 Jan; 1(8316):130. PubMed ID: 6129447
    [No Abstract]   [Full Text] [Related]  

  • 97. Comparison of sustained-release nifedipine and temperature biofeedback for treatment of primary Raynaud phenomenon. Results from a randomized clinical trial with 1-year follow-up.
    Arch Intern Med; 2000 Apr; 160(8):1101-8. PubMed ID: 10789602
    [TBL] [Abstract][Full Text] [Related]  

  • 98. [Treatment of vibration-induced disease with corinfar].
    Sukharevskaia TM; Loseva MI; Pakhomova AM; Bolotnova TV
    Gig Tr Prof Zabol; 1989; (4):37-9. PubMed ID: 2744569
    [TBL] [Abstract][Full Text] [Related]  

  • 99. [Therapeutic (im)possibilities in Raynaud's phenomenon].
    Smilde TJ; Wollersheim H
    Ned Tijdschr Geneeskd; 1996 Feb; 140(7):352-7. PubMed ID: 8628419
    [No Abstract]   [Full Text] [Related]  

  • 100. Prevention of predictable Raynaud's phenomenon by sublingual nifedipine.
    Miller FW; Love LA
    N Engl J Med; 1987 Dec; 317(23):1476. PubMed ID: 3683482
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.